Investor Presentation First Nine Months of 2023

101 Investor presentation First nine months of 2023 Novo NordiskⓇ MASH patient journey underscores key barriers to overcome for Novo Nordisk to be successful ~22 million people are expected to live with MASH F2-F4c by 2030 Global patients (in millions) 25 Hurdles 20 20 15 10 MASH prevalence Low disease awareness Inadequate patient No treatment referrals¹ options No prognostic biomarker Few patients receiving diagnosis 0 5 Prevalence Diagnosed Access Build strong presence . Create urgency to treat in MASH Build strong speciality-referral process Engage Endos, Hepas and PCPS • Market preparation priorities Increase diagnosis rate Momentum towards NITs in clinical practice and guidelines NITs for diagnosis, screening and monitoring High expected investment level ○ Low expected investment level MASH: Metabolic dysfunction-associated steatohepatitis; Endos: endocrinologist; PCP: primary care physician; NIT: Non-invasive tests; 'Referrals and identification; Hepas: hepatologists; F: Fibrosis stage Source: Estes C, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 2018 Evidence generation Build understanding of importance of addressing underlying cause of disease Stop clinical progression amongst physicians and payers

View entire presentation